Edgewise Therapeutics, Inc.

Edgewise Therapeutics, Inc. (NASDAQ: EWTX) is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines for severe muscle diseases. The company's mission centers on improving the lives of patients facing serious muscle disorders through a science-driven approach that prioritizes patient needs and unmet medical requirements.

The company operates through a proprietary, muscle-focused drug discovery platform that combines foundational expertise in muscle biology with small molecule engineering capabilities. This platform utilizes custom-built high-throughput and translatable systems designed to measure integrated muscle function in whole organ extracts, enabling the identification of small molecule precision medicines that regulate key proteins in muscle tissue. The platform initially focuses on rare neuromuscular and cardiac diseases.

Edgewise's clinical pipeline includes sevasemten, its most advanced product candidate, an orally administered allosteric selective fast myofiber myosin inhibitor designed to address contraction-induced muscle injury in dystrophinopathies, including Duchenne muscular dystrophy and Becker muscular dystrophy. The company estimates approximately 35,000 individuals living with Duchenne and 12,000 with Becker across the United States, European Union-5 countries, and Japan. Sevasemten has received Fast Track designation and Orphan Drug Designation from the FDA.

In the cardiovascular space, the company is developing EDG-7500, a novel oral selective cardiac sarcomere modulator designed to address hypertrophic cardiomyopathy by slowing early contraction velocity and improving impaired cardiac relaxation. EDG-15400, a second cardiac sarcomere modulator, is in Phase 1 development targeting heart failure with preserved ejection fraction. Additionally, the company is advancing EDG-003, a preclinical discovery program exploring candidates for cardiometabolic diseases.

Edgewise has retained global development and commercialization rights to all programs and intends to build a focused commercial organization in the United States while evaluating strategic partnerships for international markets. The company's website is www.edgewisetherapeutics.com.